Online inquiry

IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10073MR)

This product GTTS-WQ10073MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10073MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14185MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ10123MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LAG-525
GTTS-WQ6435MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ15106MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ1774MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ8725MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ4372MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ7196MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW